Annovis CEO eyes spring breakthrough for Alzheimer’s drug
Annovis Bio says its Phase 3 buntanetap trial in 760 Alzheimer’s patients passed an independent DSMB safety review and is progressing toward an FDA milestone expected in March–April, with safety data from Parkinson’s studies cited as supportive of a broader neurodegenerative program.
Why it mattersDSMB cleared Phase 3 safety data and an FDA milestone is expected in March–April.
People Mentioned
Maria MaccecchiniKyle Umipig